Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-29T05:02:38.029Z Has data issue: false hasContentIssue false

3 - Pharmaceutical strategy and the evolving role of merger and acquisition

Published online by Cambridge University Press:  05 November 2012

Lawton Robert Burns
Affiliation:
University of Philadelphia
Get access

Summary

It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change.

Introduction

The sections in this chapter deal with a common set of topics: horizontal consolidation, merger and acquisition (M&A), advantages of size, economies of scale and scope, diversification, and industry concentration. These topics all interrelate around the fundamental issue in industrial organization: how best to organize firms and markets in order to achieve optimal economic performance?

Consolidation has been rampant in most sectors of the healthcare industry since the 1980s and 1990s. Indeed, the industry was the second most active in terms of M&A activity (behind finance) between 2008 and 2009. In the pharmaceutical sector, the prior decades had been a time of growth and consolidation, as companies leveraged both size and scale in bringing drugs to market. The current landscape, however, is one of new challenges requiring new approaches to their solution. Companies are faced with internal pressures of declining pipeline productivity and compressed timelines, external pressures of patent expiry and pricing, and the uncertain implications of healthcare reform. Accompanying this evolution of challenges has been an evolution in the strategic approaches taken by pharmaceutical companies to best position themselves for success in the upcoming years.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Saigol, LinaConsolidation is Key to Pharma StabilityFinancial Times 10 2009 20Google Scholar
Goldsmith, JeffHas the US Health Technology Sector Run Out of GasHarvard Business Review Blog 12 2010Google Scholar
Cacciotti, JerryHewitt, JeffShew, BillShadow of a DroughtNew YorkOliver Wyman 2011Google Scholar
Business InsightsThe Evolving Pharma M&A Landscape 22 2009
Munos, BernardLessons From 60 Years of Pharmaceutical InnovationNature Reviews Drug Discovery 8 2009 959CrossRefGoogle ScholarPubMed
Acemoglu, DaronLinn, JoshuaMarket Size in Innovation: Theory and Evidence from the Pharmaceutical IndustryQuarterly Journal of Economics 119 2004 1049CrossRefGoogle Scholar
Grabowski, HenryVernon, JohnThe Determinants of Pharmaceutical Research and Development ExpendituresJournal of Evolutionary Economics 10 2000 201CrossRefGoogle Scholar
Bernstein, AllianceThe New Industrial Revolution: De-verticalization on a Global ScaleNew YorkAllianceBernstein 2005Google Scholar
Rockoff, JonathanWinslow, RonDrug Makers Refill Parched PipelinesWall Street Journal 2011 A1Google Scholar
Herper, MatthewPfizer’s Radical SurgeryForbes 23 2011 86Google Scholar
Behnke, NilsHueltenschmidt, NorbertChanging Pharma’s Innovation DNAIn Vivo 2011 56Google Scholar
Munos, BernardHow to Avert Biopharma’s R&D CrisisIn Vivo 2011 58Google Scholar
Licking, Ellen F.Sanofi/Genzyme: Emblematic of What Big Pharma’s Buying NowIn Vivo 2011 48Google Scholar
Rockoff, JonathanInada, MihoDrug Firms Up Ante in JapanWall Street Journal 2011 B1Google Scholar
Regalado, AntonioDrug Development’s Preclinical BottleneckStart-Up 1997 26Google Scholar
Cassak, DavidLongman, RogerRegalado, AntonioMerger Mania – Faith or Folly?In Vivo 1996 4Google Scholar
Longman, RogerHave Problem? Try M&AIn Vivo 1999 59Google Scholar
McKinsey & CompanyDoes Market Concentration Create Market Value?In Vivo 1998 33Google Scholar
Steverman, BenM&A: Will the Recession Spark a Rebound?Business Week 2009 www.businessweek.com/investor/content/jan2009/pi20090126_262047.htmGoogle Scholar
Grabowski, HenryKyle, MargaretMergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D ProductivityGugler, KlausYurtoglu, B. BurcinThe Economics of Corporate Governance and MergersNorthampton, MAElgar Publishing 2008 262Google Scholar
Said, CarolynPfizer to Open Research Center in SF’s Mission BaySan Francisco Chronicle 2011 D1Google Scholar
Hirschler, BenTop 6 Drugs Tipped to be Biotech Products by 2014Reuters 2009 www.reuters.com/article/idUSTRE55G4PI20090617Google Scholar
Burns, Lawton R.Pauly, MarkIntegrated Delivery Networks: A Detour on the Road to Integrated Health CareHealth Affairs 21 2002 128CrossRefGoogle ScholarPubMed
Besanko, DavidDranove, DavidShanley, MarkEconomics of StrategyNew YorkJohn Wiley 2000Google Scholar
Danzon, PatriciaEpstein, AndrewNicholson, SeanMergers and Acquisitions in the Pharmaceutical and Biotech IndustriesManagerial and Decision Economics 28 2007 307CrossRefGoogle Scholar
Marchant, JeanetteBiotech M&A StrategiesLondonBusiness Insights 2008Google Scholar
Standard & PoorsIndustry Surveys: Healthcare – PharmaceuticalsNew York 1991Google Scholar
Standard & PoorsIndustry Surveys: Healthcare – PharmaceuticalsNew York 1999Google Scholar
Ravenscraft, DavidLong, WilliamPaths to Creating Value in Pharmaceutical MergersKaplan, StevenMergers and ProductivityChicago, ILUniversity of Chicago Press 2000 287Google Scholar
RavenscraftLongPaths to Creating Value”; Susan Pulliam and Elyse Tanouye, “Drug Industry Consolidation May Not be OverWall Street Journal 1994 C1Google Scholar
Standard & PoorsIndustry Surveys: Healthcare – PharmaceuticalsNew York 1994Google Scholar
Standard & PoorsIndustry Surveys: Healthcare – PharmaceuticalsNew York 1999Google Scholar
Longman, RogerAfter Roche/Genentech: Pharma’s Focus on Efficiencies, Not InnovationIn Vivo 2008 22Google Scholar
Rubin, JamiTsang, FlorencePaquette, SebastianThe Mega-Merger Disconnect: A Fork in the Road to GrowthNew YorkGoldman Sachs 2010Google Scholar
Longman, RogerMerck Buys Schering-Plough – and TimeIn Vivo 2009 26Google Scholar
Jannarone, JohnMerck Tests an R&D RemedyWall Street Journal 2009 C10Google Scholar
Pursche, WilliamPharmaceuticals: The Consolidation isn’t OverMcKinsey Quarterly 2 1996 110Google Scholar
Kalorama InformationPharmaceutical and Biopharmaceutical Market to 2015 Pipeline ReportRockville, MDKalorama 2010Google Scholar
Tufts Center for the Study of Drug DevelopmentImpact Report 11 2009
Higgins, MatthewRodriguez, DanielThe Outsourcing of R&D Through Acquisitions in the Pharmaceutical IndustryJournal of Financial Economics 80 2006 351CrossRefGoogle Scholar
Herper, MatthewFive Molecules That Will Change The WorldForbes 2003 http://www.forbes.com/2003/07/02/cz_mh_0702molecules.htmlGoogle Scholar
Deogun, NikhilHarris, GardinerLipin, StevenLangreth, RobertIn Biggest Hostile Bid, Pfizer Offers $80 Billion for Warner-LambertWall Street Journal 1999 A1Google Scholar
Lipin, StevenMixing it UpWall Street Journal 1999 A1Google Scholar
Tanouye, ElyseMergers Will Keep Shuffling Rankings of Drug MakersWall Street Journal 1995 B4Google Scholar
Barrett, AmyBig Pharma: Getting Too Big for its Own Good?Business Week 2002 74Google Scholar
PhRMA Touts Medications’ EfficacyChain Drug Review 24 2002
Longman, RogerRenewing NovartisIn Vivo 2001 17Google Scholar
Bilous, AlexandreFrench and German Unions Respond to Hoechst/Rhône-Poulenc MergerEuropean Industrial Relations Observer 14 1999Google Scholar
Capell, KerryAstraZeneca: A Drug Megamerger that’s WorkingBusiness Week 1999Google Scholar
Burton, ThomasLipin, StevenMoore, StephenUpjohn and Pharmacia Sign $6 Billion MergerWall Street Journal 1995 A3Google Scholar
Sorkin, AndrewSanofi Makes its Bid for Aventis; It is Quickly Rejected as ‘Inferior,’New York Times 2004 C1Google Scholar
Senior, MelanieMorrison, ChristopherThe Best Defense is a Good Offense: Sanofi’s Bid for AventisIn Vivo 2004 76Google Scholar
Shimanura, KazuhiroSinger, JasonJapanese Drug Makers to CombineWall Street Journal 2004 A2Google Scholar
Landers, PeterJapan is Urging its Drug Firms to Merge, Citing Need for HeftWall Street Journal 2002 B2Google Scholar
Roche and Chugai Blaze a Trail . . . but Will Anyone FollowIn Vivo 2002 39
Landers, PeterMerck, Pfizer Battle in JapanWall Street Journal 2003 B4Google Scholar
De Vré, RaymondGoeller, SimonPawlu, ChristianPharma’s Generics Opportunity in Central and Eastern EuropeMcKinsey Quarterly 2008 1Google Scholar
Schweizer, LarsKnowledge Transfer and R&D in Pharmaceutical Companies: A Case StudyJournal of Engineering and Technology Management 22 2005 315CrossRefGoogle Scholar
Danzon, PatriciaNicholson, SeanPereira, Nuno SousaProductivity in Biotech-Pharmaceutical R&D: The Role of Experience and AlliancesJournal of Health Economics 24 2005 317CrossRefGoogle Scholar
Garg, RajeshBerggren, RoyHolcomb, MicheleThe Value of Scale in Pharma’s FutureIn Vivo 2001 78Google Scholar
Kearney, A. T.Saint Joseph’s University Pharmaceutical Marketing StrategyNew YorkA. T. Kearney 1999Google Scholar
Arlington, SteveBarnett, SamHughes, SimonPalo, JoePharma 2010: The Threshold of InnovationNew YorkIBM Business Consulting Services 2003Google Scholar
Troubling Numbers for Big Pharma ConsolidationIn Vivo 2000 2
Dvorin, JeffreyCreating Glaxo WellcomeIn Vivo 1999 5Google Scholar
Fisher, LawrencePost-Merger Integration: How Novartis Became No. 1Strategy + Business 11 1998 2Google Scholar
AccentureAchieving High Performance in PharmaceuticalsNew YorkAccenture 2007Google Scholar
Cohen, Wesley M.Levin, Richard C.Empirical Studies of Innovation and Market StructureSchmalensee, R.Willig, R. D.Handbook of Industrial OrganizationAmsterdamElsevier 1989 1059Google Scholar
Istvan, JayWolcott, RogerIs Bigger Really Better?In Vivo 1996 11Google Scholar
CohenLevinEmpirical Studies”; William Comanor, “The Political Economy of the Pharmaceutical IndustryJournal of Economic Literature 24 1986 1178Google Scholar
Lehman BrothersPharma PipelinesNew YorkLehman Bros 2002Google Scholar
Cockburn, IainHenderson, RebeccaScale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical ResearchJournal of Health Economics 20 2001 1033CrossRefGoogle ScholarPubMed
Jensen, ElizabethResearch Expenditures and the Discovery of New DrugsJournal of Industrial Economics 36 1987 83CrossRefGoogle Scholar
Henderson, RebeccaCockburn, IainScale, Scope, and Spillovers: The Determinants of Research Productivity in Drug DiscoveryRAND Journal of Economics 27 1996 32CrossRefGoogle ScholarPubMed
Markman, GideonEspina, MaritzaPatents as Surrogates for Inimitable and Non-Substitutable ResourcesJournal of Management 30 2004 529CrossRefGoogle Scholar
Arora, AshishGambardella, AlfonsoMagazzini, LauraPammolli, FabioA Breath of Fresh Air? Firm Type, Scale, Scope, and Selection Effects in Drug DevelopmentManagement Science 55 2009 1638CrossRefGoogle Scholar
Mertens, GilbertBeyond the Blockbuster DrugLondonBusiness Insights 2005Google Scholar
Pisano, GaryScience Business: The Promise, The Reality, and The Future of BiotechBoston, MAHarvard Business School Press 2006Google Scholar
Kandybin, AlexanderKihn, MartinRaising Your Return on Innovation InvestmentStrategy + Business 35 2004 38Google Scholar
Barrett, AmyCapell, KerryBig Pharma: Getting Too Big for its Own Good?Business Week 2002 74Google Scholar
Sahu, VikramTracey, MarkMurphy, JohnTracking the ‘X Factor’ – Pipeline ValuationsGlobal Equity Research ReportNew YorkGoldman Sachs 2002Google Scholar
CenterWatch 2000 Troubling Numbers for Big Pharma ConsolidationIn Vivo 18Google Scholar
Hassan, MahmudPatro, DilipTuckman, HowardWang, XiaoliDo Mergers and Acquisitions Create Shareholder Wealth in the Pharmaceutical IndustryInternational Journal of Pharmaceutical and Healthcare Marketing 1 2007 58CrossRefGoogle Scholar
Skrepnek, GrantLawson, KennethThe Effect of Merger and Acquisition Activity on Shareholder Returns in the Pharmaceutical IndustryJournal of Research in Pharmaceutical Economics 11 2001 19CrossRefGoogle Scholar
Andrade, GregorMitchell, MarkStafford, ErikNew Evidence and Perspectives on MergersJournal of Economic Perspectives 15 2001 103CrossRefGoogle Scholar
Bruner, R.Does M&A Pay? A Survey of Evidence for the Decision MakerJournal of Applied Finance 12 2002 48Google Scholar
Bradley, MichaelDesai, AnandKim, E. HanSynergistic Gains from Corporate Acquisitions and their Division between the Stockholders of Target and Acquiring FirmsJournal of Financial Economics 21 1988 3CrossRefGoogle Scholar
Agarwal, SumitDesai, SanjayHolcomb, MicheleOberoi, ArjunUnlocking the Value in Big PharmaMcKinsey Quarterly 2 2001 64Google Scholar
McKinsey and CompanyDoes Market Concentration Create Market Value?In Vivo 1998 33Google Scholar
Hill, RaymondPeterseim, MarkusMaximizing Pharmaceutical HealthIn Vivo 17 1999 34Google Scholar
Kearney, A. T.A Prescription for Pharmaceutical HealthChicago, ILA. T. Kearney 2002Google Scholar
Gilbert, JimHenske, PrestonSingh, AshishRebuilding Big Pharma’s Business ModelIn Vivo 2003 73Google Scholar
Kay, ChrisDrugmaker Acquisitions to Weigh on Credit Ratings, Moody’s SaysBloomberg 2010Google Scholar
Koenig, MichaelMezick, ElizabethImpact of Mergers and Acquisitions on Research Productivity within the Pharmaceutical IndustryScientometrics 59 2004 157Google Scholar
Ameet, MallikGary, PinkusScott, ShefferBiopharma’s Capacity CrunchMcKinsey Quarterly 2002 9Google Scholar
Henske, Prestonvan Biesen, TimCollaborating for Better R&D ProductivityIn Vivo 2009 60Google Scholar
Wang, ShirleyWyeth to Focus Research Efforts on Fewer DiseasesWall Street Journal 2008Google Scholar
Rockoff, JonathanPfizer Plans Layoffs in ResearchWall Street Journal 2009Google Scholar
Whalen, JeanneSanofi Overhauls R&D to Help Costs, PipelineWall Street Journal 2009 B3Google Scholar
Apgar, MahlonWhat Every Leader Should Know about Real EstateHarvard Business Review 2009 100Google Scholar
Welton, RichardWanted: New Molecules – How Large Pharma Sources InnovationPulse Magazine 2010 13Google Scholar
Lawyer, PeteAndrew, JamesTollman, PeterSilverstein, MartinPayback: Making Innovation Count in Uncertain TimesIn Vivo 2007 1Google Scholar
Melanie SeniorGSK’s Virtual Proof-of-Concept Unit in Tune with Lilly’s ChorusIn Vivo 2009 16Google Scholar
Senior, MelanieGSK Tries to Mimic Real-World BiotechIn Vivo 2009 46Google Scholar
Longman, RogerCan Out-Partnering Help Vault Pfizer over the ‘Second Cliff’?In Vivo 2008 28Google Scholar
Lash, AlexSanofi Makes its Biggest ‘External’ Play Yet with Long-Term Regeron DealIn Vivo 2009 12Google Scholar
LaMattina, JohnThe Impact of Mergers on Pharmaceutical R&DNature Reviews Drug Discovery 10 2011 559CrossRefGoogle ScholarPubMed
Sirower, MarkThe Synergy Trap: How Companies Lose the Acquisition GameNew YorkFree Press 1997Google Scholar
Barfield, R.Creating Value through MergersBanker 1988 24Google Scholar
Ravenscraft, DavidScherer, F. M.The Profitability of MergersInternational Journal of Industrial Organization 7 1989 101CrossRefGoogle Scholar
Grabowski, HenryKyle, MargaretMergers, Acquisitions and AlliancesDanzon, PatriciaNicholson, SeanHandbook on the Economics of the Biopharmaceutical IndustryAmsterdamElsevier
Ahuja, GautamLampert, CurbaTandon, VivekMoving Beyond Schumpeter: Management Research on the Determinants of Technological InnovationAcademy of Management Annals 2 2008 1CrossRefGoogle Scholar
Greiner, LarryEvolution and Revolution as Organizations GrowHarvard Business Review 1972 37Google Scholar
Hitt, MichaelIreland, R. DuaneHarrison, JeffreyMergers and Acquisitions: A Value Creating or Value Destroying StrategyHitt, MichaelFreeman, R. EdwardHarrison, JeffreyThe Blackwell Handbook of Strategic ManagementMalden, MABlackwell Business 2001 384Google Scholar
Acs, Z. J.Audretsch, D. B.Innovation, Market Structure, and Firm SizeReview of Economics and Statistics 71 1987 567CrossRefGoogle Scholar
Henderson, RebeccaOrsenigo, LuigiPisano, GaryThe Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions among Scientific, Institutional, and Organizational ChangesMowery, DavidNelson, RichardSources of Industrial LeadershipCambridge University Press 1999 267CrossRefGoogle Scholar
Nelson, RichardWinter, SidneyAn Evolutionary Theory of Economic ChangeCambridge, MAHarvard University Press 1982Google Scholar
Jewkes, J.Sawers, D.Stillerman, R.The Sources of InventionLondonMacmillan 1958Google Scholar
Jack, AndrewPharma Split on Nature of Mergers as Kill or CureFinancial Times 2009Google Scholar
Simonian, HaigMaking Drugs FasterFinancial Times 2010 33Google Scholar
Beer, MichaelHigh Commitment, High PerformanceSan Francisco, CAJossey-Bass 2009Google Scholar
Mittra, JamesThe Socio-Political Economy of Pharmaceutical Mergers: A Case Study of Sanofi and AventisTechnology Analysis and Strategic Management 18 2006 473CrossRefGoogle Scholar
Mittra, JamesLife Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large FirmsTechnology Analysis and Strategic Management 19 2007 279CrossRefGoogle Scholar
Anand, JaideepOriani, RaffaeleVassolo, RobertoAlliance Activity as a Dynamic Capability in the Face of Discontinuous Technological ChangeOrganization Science 21 2010 1213CrossRefGoogle Scholar
Licking, Ellen F.Morrison, ChristopherPharma: Serious About Change?In Vivo 2010 34Google Scholar
Jung, JeffreyWang, AndyRx for Pharmaceutical Companies: Internal Collaboration is the Key to Improved InnovationSomers, NYIBM Institute for Business Value 2002Google Scholar
Jung, JeffreyCreating Breakthrough Innovation During a Pharmaceutical Merger or AcquisitionSomers, NYIBM Institute 2002Google Scholar
Pisano, GaryThe Development FactoryBoston, MAHarvard Business School Press 1997Google Scholar
Deloitte ResearchCollaborative Knowledge Networks: Accelerating Pharmaceutical R&D in the New MillenniumNew YorkDeloitte Research 2002Google Scholar
David, EricMehta, AmitNorris, TroyNew Frontiers in Pharma R&D InvestmentMcKinsey Quarterly 2010 1Google Scholar
Boyle, MatthewGrowing against the GrainFortune 2004 148Google ScholarPubMed
Erickson, DeborahAmgen Moves Beyond ProteinsIn Vivo 2004 18Google Scholar
Garnier, Jean-PierreRebuilding the R&D Engine in Big PharmaHarvard Business Review 86 2008 69Google Scholar
Huckman, RobertPisano, GaryRennella, MarkWyeth Pharmaceuticals: Spurring Scientific Creativity with MetricsBoston, MAHarvard Business School Publishing 2007Google Scholar
Henderson, RebeccaCockburn, IainMeasuring Competence? Exploring Firm Effects in Pharmaceutical ResearchStrategic Management Journal 15 1994 63CrossRefGoogle Scholar
Landers, PeterMerck Ends Research on Once Promising AntidepressantWall Street Journal 2003 B1Google Scholar
Barrett, AmyCarey, JohnArndt, MichaelFeeding the PipelineBusiness Week 2003 78Google Scholar
Pil, FritsHolweg, MatthiasExploring Scale: The Advantages of Thinking SmallSloan Management Review 2003 33Google Scholar
Gartenmann, ThomasGuy, PhilippeRx Industry Post M&A Integration, Part I: Marketing and SalesIn Vivo 1997 20Google Scholar
Erickson, DeborahNovartis Bucks the TrendIn Vivo 2004 43Google Scholar
PilHolwegExploring Scale”; Lawrence Fisher, “The New Architecture of Biomedical ResearchStrategy + Business 33 2003 58Google Scholar
Burton, ThomasBy Learning from Failures, Lilly Keeps Drug Pipeline FullWall Street Journal 2004 A1Google Scholar
Ratner, MarkHow Experimental Medicine is Affecting Big PharmaIn Vivo 2004 59Google Scholar
Landers, PeterWith Dry Pipelines, Big Drug Makers Stock up in JapanWall Street Journal 2003 A1Google Scholar
Landers, PeterDrug Industry’s Big Push into Technology Falls ShortWall Street Journal 2004 A1Google Scholar
Longman, RogerLilly’s Chorus ExperimentIn Vivo 2007 35Google Scholar
Silverman, EdLilly Tries to Buy TimeIn Vivo 2009 26Google Scholar
AccentureAchieving High Performance in PharmaceuticalsNew YorkAccenture 2007Google Scholar
Peterson, AnnaVlak, AugustThe Missing Link in Innovative ResearchStrategy + Business 2011Google Scholar
Tkaczyk, ChristopherEncouraging InnovationFortune 2009 22Google Scholar
Larsson, RikandFinkelstein, SydneyIntegrating Strategic, Organizational, and Human Resource Perspectives on Mergers and Acquisitions: A Case Survey of Synergy RealizationOrganization Science 10 1999 1CrossRefGoogle Scholar
Haspeslagh, PhillippeJemison, DavidManaging Acquisitions: Creating Value Through Corporate RenewalNew YorkFree Press 1991Google Scholar
Schweizer, LarsThe Key Drivers and Success Factors for M&A Strategies in the Biotechnological and Pharmaceutical IndustryPharmaceuticals Policy and Law 5 2002 41Google Scholar
Schweizer, LarsOrganizational Integration of Acquired Biotechnology Companies into Pharmaceutical Companies: The Need for a Hybrid ApproachAcademy of Management Journal 48 2005 1051CrossRefGoogle Scholar
Erickson, DeborahWanted: Drug HuntersIn Vivo 2003 45Google Scholar
Hamel, GaryGetz, GaryFunding Growth in an Age of AusterityHarvard Business Review 82 2004 76Google Scholar
Tzabbar, DanielWhat Helps and Hinders InnovationSloan Management Review 2009 17Google Scholar
Tzabbar, DanielAharonson, BarakAmburgey, TerryAl-Laham, AndreasWhen is the Whole Bigger Than the Sum of its Parts? Bundling Knowledge Stocks for Innovative SuccessStrategic Organization 6 2008 375CrossRefGoogle Scholar
Colvin, GeoffDisease Hunter: Gilead CEO John Martin Hit it Big with HIV Drugs – Now He’s Planning an EncoreFortune 2011 80Google Scholar
Paul, StevenMytelka, DanielDunwiddie, ChristopherHow to Improve R&D Productivity: The Pharmaceutical Industry’s Grand ChallengeNature Reviews Drug Discovery 9 2010 203CrossRefGoogle ScholarPubMed
Simons, JohnLilly goes off ProzacFortune 2004 179Google ScholarPubMed
Herper, MatthewRallying Pharma’s RebelsForbes 2011 95Google Scholar
Longman, RogerJumpstart to ProductsIn Vivo 2004 17Google Scholar
Sims, NelsonGueth, AntonManaging Alliances at LillyIn Vivo 19 2001 71Google Scholar
Longman, RogerWhy Doesn’t Pharma Get Smaller?In Vivo 2009 26Google Scholar
Longman, RogerPfizer/Wyeth: Industrializing Pharma?In Vivo 2009 36Google Scholar
Whalen, JeanneGreil, AnitaGenerics, Vaccines Help Novartis Profit Rise 7%Wall Street Journal 2008 B6Google Scholar
Andrew, JackNew GSK Boss Says Will Try to Cut ‘Nasty Surprises,’Financial Times13 2008Google Scholar
2008
2008
Loftus, PeterDrug Makers Move to DiversifyWall Street Journal 2008 B4Google Scholar
Launder, WilliamHenning, EykBattle Heats Up for Drug FirmWall Street Journal 2010 B2Google Scholar
Butler, C. AnthonyMark, PurcellMajor Pharmaceuticals: Divergent Business Models 2010–2015LondonBarclays Capital 2010Google Scholar
Peter, Loftus 2008
Merrill, JessicaBristol Spins Off Mead Johnson in Stock Swap: Finally Pure PharmaIn Vivo 2009 19Google Scholar
Diller, WendyCan BMS – With the Help of Medarex and Others – Deliver on Innovation?In Vivo 2009 16Google Scholar
Lichtenberg, FrankIndustrial De-Diversification and its Consequences for ProductivityJournal of Economic Behavior and Organization 18 1992 427CrossRefGoogle Scholar
Guth, RobertWall Street Journal 2010
Dimasi, JosephRisks in New Drug Development: Approval Success Rates for Investigational DrugsClinical Pharmacology and Therapeutics 69 2001 297CrossRefGoogle ScholarPubMed
Hensley, ScottBiggest Drug Firm Faces Generics but has an Edge: its Very BignessWall Street Journal 2004 A1Google Scholar
Jack, AndrewSupply Running LowFinancial Times 2011 9Google Scholar
Whalen, JeanneHurdles Multiply for Latest DrugsWall Street Journal 2011 B1Google Scholar
Carruthers, JanetRod, MichelAshill, NicholasPurchaser-Provider Interaction in UK Public Health: Improving Stakeholder CooperationInternational Journal of Pharmaceutical and Healthcare Marketing 1 2007 12CrossRefGoogle Scholar
LeClerc, OlivierLeung, MandySumner, HeatherExploring the Full Potential of Risk-Sharing Agreements between Pharmaceutical Companies and PayorsIn Vivo 2010 56Google Scholar
DeloittePharma’s New US Commercial Model: Promoting the Science Not the SwagDeloitte 2009Google Scholar
Whalen, Jeanne 2008 http://online.wsj.com/article/SB120833908419819167.html?mod=todays_us_marketplace
Lindgardt, ZhenyaReeves, MartinWallenstein, JudithWaking the Giant: Business Model Innovation in the Drug IndustryIn Vivo 2008 54Google Scholar
Whalen, JeanneUK Pushback on Glaxo Drug PriceWall Street Journal 2011 B3Google Scholar
Tunis, SeanStryer, DavidClancy, CarolynPractical Clinical Trials: Increasing the Value of Clinical Research for Decision Making in Clinical and Health PolicyJournal of American Medical Association 290 2003 1624CrossRefGoogle ScholarPubMed
Truffer, ChristopherKeehan, SeanSmith, SheilaHealth Spending Projections Through 2019: The Recession’s Impact ContinuesHealth Affairs 29 2011 522CrossRefGoogle Scholar
Diller, WendyManaged Care Tackles Biotech Budget BustersIn Vivo 2004 31Google Scholar
Diller, WendyAs Specialty Pharmacy Evolves, Biotech Companies Stay TunedIn Vivo 2004 53Google Scholar
2011
Kearney, A. T.The State as a CustomerChicago, ILA. T. Kearney 2003Google Scholar
Gilbert, JimRosenberg, PaulImbalanced Innovation: The High Cost of Europe’s ‘Free Ride,’In Vivo 2004 62Google Scholar
Galvin, RobertEmployer’s Perspective on the Role of Pharma, Biotech, and Device Sectorspresentation to the Pharma, Biotech, and Device ColloquiumPrinceton, NJ 2004Google Scholar
Buxton, BrianEaston, RobertBlockbusters to New-Engine Drugs: The Key Industry ShiftIn Vivo 2003 63Google Scholar
Haley, ShirleyPharma and Academia: Finding New Ways to Join Hands for Mutual BenefitStart-Up 2009 Bridgewater, NJElsevier Business IntelligenceGoogle Scholar
Senior, MelanieLicking, Ellen F.Back to School: Big Pharmas Test New Models for Tapping AcademiaIn Vivo 2011 22Google Scholar
Rosenberg, LeonPhysician-Scientists – Endangered and EssentialScience 283 1993 331CrossRefGoogle Scholar
Gershon, ElliotMaking Progress: Does Clinical Research Lead to Breakthroughs in Basic Biomedical SciencesAcademic Medicine 42 1998 95Google ScholarPubMed
The New Role of Academia in Drug Development: New Thinking, New Competencies, New ResultsDriving New Paradigms in Clinical ResearchKansas City, MOEwing Marion Kauffman Foundation 2010
Hymowitz, CarolThe Best Innovations Come from Smart QuestionsWall Street Journal 2004 B1Google Scholar
Begley, SharonResearchers Try to Cut New Path to the PharmacyWall Street Journal 2004 A1Google Scholar
Campbell, Eric G.Gruen, Russell L.Mountford, JamesA National Survey of Physician–Industry RelationshipsNew England Journal of Medicine 356 2007 1742CrossRefGoogle ScholarPubMed
Big Trouble for Big PharmaThe Economist 2003 67

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×